Genentech Petition Rekindles Debate On Lab-Developed Test Regulation
This article was originally published in The Pink Sheet Daily
Executive Summary
With lab-developed tests increasing in number and type recently, petition calls for FDA to regulate.
You may also be interested in...
US FDA Lab Test Rule Cites Explosion In Companion Diagnostics, COVID Lessons
FDA launches what it hopes will the final push to reform the regulatory oversight system for lab-developed tests by proposing a relatively rapid transition period to require essentially all LDTs to comply with the existing regulations for in vitro diagnostics. Legislation, litigation, and industry negotiation will likely shape the final product.
US FDA’s Long Wait For Diagnostics Reform Legislation Continues
FDA is hoping Congress might take up proposed legislation governing the regulation of diagnostic tests produced in laboratories in 2023. That will make it a full decade of stalemate since FDA outlined a framework to address the new reality of personalized medicine.
“The Right Approach” To Regulating Biomarkers: An Interview With Interleukin Genetics CEO Lewis Bender (Part 3)
Setting standards in an emerging area of science is a big challenge, both for FDA and regulated industry. One diagnostics CEO thinks FDA is taking an appropriately careful approach.